AstraZeneca pauses coronavirus vaccine trial, what does this mean for markets?

Ross J Burland FXStreet

It was earlier reported that the AstraZeneca Covid-19 vaccine trial was on hold over safety concern.

See here AstraZeneca Covid-19 vaccine trial on hold over safety concern – STAT News

To elaborate, discussions about early authorizations and reports about White House pressure to speed along a coronavirus vaccine have worried the public.

The latest reports that Drug giant AstraZeneca said Tuesday it had paused global trials of its coronavirus vaccine because of unexplained illness in one of the volunteers is a real spanner in the works for risk appetite.

Further information

The company is testing its vaccine, called the Oxford vaccine which markets had high hopes for.

However, the hold up vs the concerns about moving too fast is a cocktail of contradictions which is concerning on both sides of the coin.

Earlier Tuesday, AstraZeneca joined eight other companies in signing a pledge promising they would not seek premature government approval for any coronavirus vaccine which could help to alleviate concerns to an extent.

"We, the undersigned biopharmaceutical companies, want to make clear our on-going commitment to developing and testing potential vaccines for COVID-19 in accordance with high ethical standards and sound scientific principles," a statement read that was signed by the CEOs of AstraZeneca, BioNTech GlaxoSmithKline, Johnson & Johnson, Merck, Moderna, Novavax, Pfizer and Sanofi.

"We believe this pledge will help ensure public confidence in the rigorous scientific and regulatory process by which COVID-19 vaccines are evaluated and may ultimately be approved," they added.

Nevertheless, with the stock market in a rout and risk assets struggling, this vaccine news is another problematic area for markets to recover from and we are indeed seeing downside in Asia today.

Market update since the news

The Nikkei is down some 1.5%.

Australian stocks that had kicked off Wednesday in the negative zone, pulled down by the US equities, is now down over 2%.

The Hang Seng Index is down over 1% and the SSE Composite is down over 1% also.

Author

Ross J Burland

FXStreet

Ross J Burland, born in England, UK, is a sportsman at heart. He played Rugby and Judo for his county, Kent and the South East of England Rugby team.

EUR/USD steadies near 1.1650 ahead of US Nonfarm Payrolls

EUR/USD holds ground after five days of losses, trading around 1.1650 during the Asian hours on Friday. Traders remain cautious ahead of the US Nonfarm Payrolls report, which is expected to offer further insight into labor market conditions and the Federal Reserve’s policy outlook. December NFP is forecast to show job gains of 60,000, down from 64,000 in November.

GBP/USD: Further weakness could challenge 1.3400

GBP/USD remains under unabated selling pressure on Thursday, slipping to fresh three-day lows around 1.3415 in response to further improvement in the sentiment surrounding the Greenback ahead of Friday’s key NFP data.

Gold defends $4,450, looks to the crucial US NFP report

Gold struggles to capitalize on the previous day's goodish move up from the vicinity of the $4,400 mark and attracts some sellers while defending $4,450 in the Asian session on Friday. The critical US employment details will offer more cues about the Fed's rate-cut path, which, in turn, will influence the US Dollar price dynamics and provide a fresh impetus to the non-yielding bullion.

Forecasts for Payrolls are all over the place

Yesterday’s data put the kybosh on the idea the Fed needs to cut rates fairly urgently to protect the labor market. The jobs component of the ISM services index was nicely over 50, and that rising JOLTS voluntary quits rate also points to no real heartache in labor.

2026 economic outlook: Clear skies but don’t unfasten your seatbelts yet

Most years fade into the background as soon as a new one starts. Not 2025: a year of epochal shifts, in which the macroeconomy was the dog that did not bark. What to expect in 2026? The shocks of 2025 will not be undone, but neither will they be repeated.

XRP slides as institutional and retail demand falters

Ripple is trading down for the third consecutive day on Thursday amid escalating volatility in the cyrptocurrency market. After peaking at $2.41 on Tuesday, its highest print since November 14 amid the early-year rally, XRP has quickly ran into aggressive profit-taking.